Oracle findings and outcome history for LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC) (NCT06558799).
Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
Will the results be positive?
No public readout of results found for LUNAR-4 (NCT06558799). Trial terminated Aug 2025 per SEC filing, before primary completion (Jan 2026). Active not recruiting status; single-arm design comparing to historical LUNAR-2 control. No efficacy data released.
Will the results be positive?
LUNAR-4 (NCT06558799) terminated Aug 2025 before primary completion (est. Jan 2026). No efficacy results or public readout released; sponsor cited real-world evidence as alternative, explicitly not due to safety. No positive or negative framing of this exact trial's outcome.
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Will the results be positive?
No trial-specific efficacy readout found. The sponsor’s Aug. 28, 2025 SEC filing says LUNAR-4 was terminated because real-world evidence could achieve the study objectives and explicitly says the decision was not safety-related. The cited materials do not provide final efficacy data or frame this exact Phase 2 trial as positive or negative.
Will the results be positive?
No trial-specific efficacy readout was found. Novocure publicly said on August 28, 2025 that it terminated LUNAR-4 because real-world evidence could achieve the study objectives, and said the decision was not safety-related. Later company guidance listed other topline milestones, not LUNAR-4. That supports no public positive/negative readout for this exact trial.
Public history of accepted oracle reviews and recorded outcome changes for this trial.